-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A multi-center, forward-looking cohort study aimed at assessing the safety assumption that aspirin is safe for patients with unbromed intracranial aneurysms (UIA) and 7 mm of isovascular disease (ICVD) was published recently in Neurology' authoritative journal Neurology.
this forward-looking, multi-center cohort study recruited 1,866 UIA patients with a diameter of less than 7 mm from four hospitals between January 2016 and August 2019.
researchers recorded baseline and follow-up patient information, including the use of aspirin.
the main endpoint of the study was an aneurysm rupture.
643 patients (37.2%) continued to receive aspirin treatment after a total of 4,411.4 follow-up visits per year.
12 (0.7%) of all included patients had rupture.
the annual rate of rupture (IRR) per 100 people was 0.27 (95% CI is 0.15-0.48).
0.39 per 100 people per year (95% CI is 0.21-0.72) and 0.06 (95% CI is 0.010-0.45) per year, respectively.
in multivariable analysis, uncontrolled hypertension and UIA were associated with a high incidence of aneurysm rupture, while the use of aspirin was associated with a lower incidence of aneurysm rupture.
higher IRR in the high-risk group (UIA 5-7 mm with uncontrolled hypertension) that did not take aspirin than in other groups.
, aspirin is a safe treatment for patients with small UIA and ICD.
who do not take aspirin in the high-risk group should have enhanced monitoring.
.
